-
CaseBioscience® sa pripája k tímu, ktorý získal grant od ARPA-H vo výške až 7,3 milióna dolárov na podporu bunkových terapií pri izbovej teplote
FORT COLLINS, Colorado, 2. október 2026 /PRNewswire/ – Spolo?nos? CaseBioscience® dnes oznámila svoju ú?as? v multidisciplinárnom tíme pod vedením spolo?nosti Likarda, ktorému Agentúra pre pokro?ilé výskumné projekty v oblasti zdravia (ARPA-H) udelila prostredníctvom programu… Source: Read More
-
Boehringer Ingelheim’s Survodutide Achieves up to 13.1% Weight Loss in New Phase III Trial, Alongside Significant Improvements in Glycemic Control in People with Obesity and Type 2 Diabetes
Ingelheim, Germany, October 1, 2026 — Boehringer Ingelheim today announced positive results from the Phase III SYNCHRONIZE-2 trial, which investigates the glucagon/GLP-1 receptor dual agonist survodutide (BI 456906) in adults living with… Source: Read More
-
FDA Approves Label Update for Winrevair (sotatercept-csrk) Following HYPERION Trial Data
NYSE: $MRK A Significant Update for Pulmonary Arterial Hypertension Treatment The U.S. Food and Drug Administration (FDA) has officially approved a label update for Winrevair (sotatercept-csrk), marking a meaningful step forward in the treatment of pulmonary arterial hypertension (PAH). This update incorporates clinical data from the Phase 3 HYPERION trial, providing healthcare providers and patients…
-
Breakthrough Study: Wegovy Shows Promise in Reducing Liver Fat
A Significant Shift in Obesity Treatment Recent clinical trial data has shed light on a potential new benefit for semaglutide (marketed as Wegovy). According to findings released by Novo Nordisk, the medication has demonstrated a remarkable ability to reduce liver fat in adults living with obesity and excess liver fat. The Findings at a Glance…
-
New Hope for Cholangiocarcinoma: FDA Approves Lyrfigtu (lirafugratinib)
A Significant Milestone in Cancer Treatment The landscape for treating rare bile duct cancers has shifted with the recent FDA approval of Lyrfigtu (lirafugratinib). This new medication offers a targeted therapeutic option for adult patients battling cholangiocarcinoma, a challenging malignancy of the bile ducts. Understanding Lyrfigtu Lyrfigtu is specifically designed for patients who have previously…
-
GMP Labeling Celebrates 40 Years of US Manufacturing for Regulated Industries
GRANITE BAY, Calif., Oct. 1, 2026 /PRNewswire/ — As pharmaceutical and biotechnology sectors navigate evolving global supply chain risks, GMP Labeling Inc. is utilizing Manufacturing Day 2026 to highlight its nearly 40-year history as a domestic manufacturer of critical compliance… Source: Read More
-
New Hope for Advanced Low-Grade Serous Ovarian Cancer: The Potential of Ubamatamab
NASDAQ: $REGN A Breakthrough in Ovarian Cancer Research Recent clinical findings have brought a glimmer of optimism for patients battling advanced low-grade serous ovarian cancer. A novel therapeutic agent known as ubamatamab (MUC16xCD3) has shown promising results in initial clinical trials, highlighting a potential new path forward for those who have exhausted standard treatment options.…
-
A Breakthrough in Diabetes Care: FDA Approves Once-Weekly Insulin Efsitora Alfa
A New Era for Basal Insulin Managing Type 2 diabetes just became significantly more convenient. The FDA has officially approved Onswik (insulin efsitora alfa), a revolutionary basal insulin designed to be administered just once weekly for adults living with Type 2 diabetes. This marks a major shift from the traditional daily insulin injections that millions…
-
Revolutionizing Cell Therapy: CaseBioScience Joins $7.3M ARPA-H Project for Ambient Preservation
A Breakthrough in Medical Logistics The landscape of modern medicine is shifting, and CaseBioScience is at the forefront of a major advancement. The company has officially joined a multidisciplinary team that has been awarded up to $7.3 million in funding by the Advanced Research Projects Agency for Health (ARPA-H). This significant investment aims to solve…
-
A New Frontier in Vision: BlueRock Therapeutics and the Potential of Lemiretprocel
Advancing Cell Therapy for Vision Loss The field of regenerative medicine has taken an exciting step forward. Recently, BlueRock Therapeutics, a subsidiary of Bayer, announced positive updates regarding their investigational cell therapy, lemiretprocel (OpCT-001). This therapy is specifically designed to address the challenges of vision loss caused by retinal degeneration. Understanding the Science Lemiretprocel is…
-
A New Hope: FDA Approves Atrebioz (zilurgisertib) for FOP Treatment
NASDAQ: $MIRM A Breakthrough for Rare Disease Patients The landscape of treatment for Fibrodysplasia Ossificans Progressiva (FOP) has officially changed. The FDA has recently approved Atrebioz (zilurgisertib), providing a significant new therapeutic option for both adult and pediatric patients living with this incredibly rare and debilitating condition. Understanding FOP FOP is a progressive genetic disorder…
-
B. Braun Medical Launches Introcan Safety® 2 Deep Access IV Catheter
New longer-length IV catheter, designed to increase catheter dwell time, offers fully automatic, passive needlestick protection and multi-access blood control BETHLEHEM, Pa., Oct. 1, 2026 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain… Source: Read More
-
Zasocitinib Shows Superior Efficacy Over Deucravacitinib in New Phase 3 Trial
NYSE: $TAK A Breakthrough in Psoriasis Treatment New clinical data has emerged that could reshape the treatment landscape for plaque psoriasis. Recent Phase 3 head-to-head study results demonstrate that zasocitinib has achieved superior efficacy compared to deucravacitinib in treating patients with moderate-to-severe plaque psoriasis. Understanding the Clinical Results The study, which directly compared the two…
-
New Hope for Kidney Cancer: FDA Approves Welireg and Lenvima Combination
NYSE: $MRK A Breakthrough in Renal Cell Carcinoma Treatment The U.S. Food and Drug Administration (FDA) has officially approved a significant new treatment option for patients battling advanced kidney cancer. The combination of Welireg (belzutifan) and Lenvima (lenvatinib) is now indicated for adult patients with advanced renal cell carcinoma (RCC) who have previously received treatment…
-
Sinocare Unveils Integrated Chronic Disease Management Solutions at EASD 2024
Innovation at the Heart of Chronic Care At this year’s EASD (European Association for the Study of Diabetes) annual meeting, Sinocare took center stage to showcase its latest advancements in integrated chronic disease management. As global healthcare shifts toward more patient-centric models, Sinocare is positioning itself as a leader in digital health transformation. Integrated Solutions…
-
A Beacon of Hope: UTRX-MYCN-M1 Receives FDA Orphan and Rare Pediatric Designations
A Significant Milestone for Neuroblastoma Research In a promising development for pediatric oncology, UTR Therapeutics Inc. has officially announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation to its therapeutic candidate, UTRX-MYCN-M1. This candidate is currently being developed for the treatment of neuroblastoma, a rare…
-
Sinocare Unveils Advanced Chronic Disease Management Solutions at EASD 2024
Revolutionizing Chronic Care Management At the recent EASD (European Association for the Study of Diabetes) 2024 Annual Meeting, global healthcare innovator Sinocare took center stage to showcase its latest advancements in chronic disease management. The company presented a comprehensive suite of integrated solutions designed to help patients and healthcare providers better manage diabetes and related…
-
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s Camzyos (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
NYSE: $BMY PRINCETON, N.J.–(BUSINESS WIRE) September 30, 2026 — Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten) for the treatment of symptomatic obstructive hypertrophic… Source: Read More
-
CollPlant Biotechnologies Reports Q2 2026 Financial Results and Strategic Progress
NASDAQ: $CLGN Overview of Q2 2026 Financial Performance CollPlant Biotechnologies has officially released its financial results for the second quarter ending June 30, 2026, alongside a comprehensive corporate update. The company continues to advance its mission of transforming regenerative medicine through its proprietary plant-derived recombinant human collagen (rhCollagen) technology. Key Financial Highlights During the second…
-
Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of Yusimry, a Biosimilar to Humira
CHICAGO–(BUSINESS WIRE) September 28, 2026 –Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables… Source: Read More
-
A Breakthrough for Circadian Rhythm: Vanda Pharmaceuticals Reports Positive Phase III Results
New Hope for Delayed Sleep-Wake Phase Disorder Vanda Pharmaceuticals has reached a significant milestone in sleep medicine. The company recently announced positive results from its Phase III clinical trial evaluating Hetlioz (tasimelteon) for the treatment of Delayed Sleep-Wake Phase Disorder (DSWPD). Understanding DSWPD Delayed Sleep-Wake Phase Disorder is a chronic circadian rhythm disorder characterized by…